Brief: Xspray Pharma Gets CRL From FDA
05/06/2026 09:05
BRIEF-Xspray Pharma Gets CRL From FDA June 5 (Reuters) - Xspray Pharma AB (publ) XSPRAY.ST:
SAID ON FRIDAY IT RECEIVED COMPLETE RESPONSE LETTER FROM U.S. FOOD AND DRUG ADMINISTRATION FOR NEW DRUG APPLICATION FOR NILOPKI
FDA CURRENTLY NOT ABLE TO APPROVE THE NDA
WILL ADDRESS REMAINING QUESTIONS WITH FDA
LONG‑TERM STRATEGY AND HYNAP PLATFORM REMAIN UNCHANGED
Source text for Workspace: nMFN9HmZ9h
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003